BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 10526666)

  • 1. Complex decision-making for BRCA1/2 carriers.
    Matloff ET
    Cancer J Sci Am; 1999; 5(5):266-8. PubMed ID: 10526666
    [No Abstract]   [Full Text] [Related]  

  • 2. Preventive gynecologic surgery for BRCA1/2 carriers--information for decision-making.
    Quillin JM; Boardman CH; Bodurtha J; Smith T
    Gynecol Oncol; 2001 Oct; 83(1):168-70. PubMed ID: 11585435
    [No Abstract]   [Full Text] [Related]  

  • 3. Prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers.
    Rebbeck TR
    J Clin Oncol; 2000 Nov; 18(21 Suppl):100S-3S. PubMed ID: 11060335
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Histology of prophylactically removed ovaries from BRCA1 and BRCA2 mutation carriers compared with noncarriers in hereditary breast ovarian cancer syndrome kindreds.
    Casey MJ; Bewtra C; Hoehne LL; Tatpati AD; Lynch HT; Watson P
    Gynecol Oncol; 2000 Sep; 78(3 Pt 1):278-87. PubMed ID: 10985881
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemoprevention options for BRCA1 and BRCA2 mutation carriers.
    Eeles RA; Powles TJ
    J Clin Oncol; 2000 Nov; 18(21 Suppl):93S-9S. PubMed ID: 11060334
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevention and therapy for BRCA1/2 mutation carriers and women at high risk for breast and ovarian cancer.
    Kuschel B; Lux MP; Goecke TO; Beckmann MW
    Eur J Cancer Prev; 2000 Jun; 9(3):139-50. PubMed ID: 10954253
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Breast & ovarian cancer. Issues in risk assessment.
    Caro SW
    Adv Nurse Pract; 1999 Aug; 7(8):26-32; quiz 33-4. PubMed ID: 10745719
    [No Abstract]   [Full Text] [Related]  

  • 8. Risk of breast cancer in carriers of BRCA gene mutations.
    Birkmeyer JD; Welch HG
    N Engl J Med; 1997 Sep; 337(11):787-8; author reply 789. PubMed ID: 9289638
    [No Abstract]   [Full Text] [Related]  

  • 9. A high occurrence of BRCA1 and BRCA2 mutations among Czech hereditary breast and breast-ovarian cancer families.
    Machácková E; Foretová L; Navrátilová M; Valík D; Claes K; Messiaen L
    Cas Lek Cesk; 2000 Oct; 139(20):635-7. PubMed ID: 11192759
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BRCA1 and BRCA2 mutation carriers as potential candidates for chemoprevention trials.
    Levy-Lahad E; Krieger M; Gottfeld O; Renbaum P; Klein G; Eisenberg S; Lahad A; Kaufman B; Catane R
    J Cell Biochem Suppl; 2000; 34():13-8. PubMed ID: 10762009
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hereditary breast cancer.
    Robson ME; Boyd J; Borgen PI; Cody HS
    Curr Probl Surg; 2001 Jun; 38(6):387-480. PubMed ID: 11375625
    [No Abstract]   [Full Text] [Related]  

  • 12. Frequency of BRCA1 and BRCA2 mutations in a clinic-based series of breast and ovarian cancer families.
    Vaziri SA; Krumroy LM; Rostai M; Casey G
    Hum Mutat; 2001; 17(1):74. PubMed ID: 11139249
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The quality of life associated with prophylactic treatments for women with BRCA1/2 mutations.
    Grann VR; Jacobson JS; Sundararajan V; Albert SM; Troxel AB; Neugut AI
    Cancer J Sci Am; 1999; 5(5):283-92. PubMed ID: 10526669
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Factors associated with decisions about clinical BRCA1/2 testing.
    Armstrong K; Calzone K; Stopfer J; Fitzgerald G; Coyne J; Weber B
    Cancer Epidemiol Biomarkers Prev; 2000 Nov; 9(11):1251-4. PubMed ID: 11097234
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BRCA: the breast, ovarian, and other cancer genes.
    Boyd J
    Gynecol Oncol; 2001 Mar; 80(3):337-40. PubMed ID: 11263927
    [No Abstract]   [Full Text] [Related]  

  • 16. Risk of breast cancer in carriers of BRCA gene mutations.
    Orlando R
    N Engl J Med; 1997 Sep; 337(11):787; author reply 789. PubMed ID: 9289637
    [No Abstract]   [Full Text] [Related]  

  • 17. [Breast cancer genetics. BRCA1 and BRCA2: the main genes for disease predisposition].
    Ruiz-Flores P; Calderón-Garcidueñas AL; Barrera-Saldaña HA
    Rev Invest Clin; 2001; 53(1):46-64. PubMed ID: 11332051
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic counseling in hereditary breast/ovarian cancer in Israel: psychosocial impact and retention of genetic information.
    DiCastro M; Frydman M; Friedman I; Shiri-Sverdlov R; Papa MZ; Goldman B; Friedman E
    Am J Med Genet; 2002 Aug; 111(2):147-51. PubMed ID: 12210341
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CAG and GGC repeat polymorphisms in the androgen receptor gene and breast cancer susceptibility in BRCA1/2 carriers and non-carriers.
    Kadouri L; Easton DF; Edwards S; Hubert A; Kote-Jarai Z; Glaser B; Durocher F; Abeliovich D; Peretz T; Eeles RA
    Br J Cancer; 2001 Jul; 85(1):36-40. PubMed ID: 11437399
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutational analyses of BRCA1 and BRCA2 in Ashkenazi and non-Ashkenazi Jewish women with familial breast and ovarian cancer.
    Shiri-Sverdlov R; Oefner P; Green L; Baruch RG; Wagner T; Kruglikova A; Haitchick S; Hofstra RM; Papa MZ; Mulder I; Rizel S; Bar Sade RB; Dagan E; Abdeen Z; Goldman B; Friedman E
    Hum Mutat; 2000 Dec; 16(6):491-501. PubMed ID: 11102978
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.